MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3

Cheng,Ming; Duan,Ping‑Guo; Gao,Zhi‑Zeng; Dai,Min

doi:10.3892/or.2020.7814

MicroRNA‑487b‑3p inhibits osteosarcoma chemoresistance and metastasis by targeting ALDH1A3

Authors:
- Ming Cheng
- Ping‑Guo Duan
- Zhi‑Zeng Gao
- Min Dai
View Affiliations

Affiliations: Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: October 19, 2020 https://doi.org/10.3892/or.2020.7814
Pages: 2691-2700

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis and chemoresistance indicate poor prognosis in patients with osteosarcoma (OS). In the present study, the expression level of microRNA(miR)‑487b‑3p in OS specimens and cell lines was found to be decreased, and the expression level of miR‑487b‑3p was associated with overall survival in patients with OS. The inhibition of miR‑487b‑3p stimulated OS cell migration and contributed to the development of chemoresistance. In contrast, the overexpression of miR‑487b‑3p significantly inhibited OS cell migration and enhanced the sensitivity of OS cells to doxorubicin treatment. In addition, the results from the present study revealed that the suppression of miR‑487b‑3p stimulates OS stemness, while the overexpression of miR‑487b‑3p suppresses OS stemness. Notably, in vivo experiments also revealed that the overexpression of miR‑487b‑3p inhibited cancer stem cell (CSC)‑induced tumor formation, and the combination treatment of miR‑487b‑3p and doxorubicin significantly inhibited CSC‑induced tumor growth. Furthermore, miR‑487b‑3p exerts its anticancer role by targeting aldehyde dehydrogenase 1 family member A3 in OS. Taken together, the results from the present study suggests that miR‑487b‑3p is a tumor suppressor and that the overexpression of miR‑487b‑3p is a novel strategy to inhibit tumor metastasis and chemoresistance in OS.

View Figures

View References

1	Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM and Getty PJ: Osteosarcoma. J Am Acad Orthop Surg. 17:515–527. 2009. View Article : Google Scholar : PubMed/NCBI
2	Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
3	Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar : PubMed/NCBI
4	Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
5	Xu M, Jin H, Xu CX, Sun B, Song ZG, Bi WZ and Wang Y: miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. Mol Ther. 23:89–98. 2015. View Article : Google Scholar : PubMed/NCBI
6	Liu C and Tang DG: MicroRNA regulation of cancer stem cells. Cancer Res. 71:5950–5954. 2011. View Article : Google Scholar : PubMed/NCBI
7	MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ and Barr MP: BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett. 428:117–126. 2018. View Article : Google Scholar : PubMed/NCBI
8	Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN and Struhl K: Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 39:761–772. 2010. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, et al: MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-familydependent chromatin remodeling. Cell. 154:311–324. 2013. View Article : Google Scholar : PubMed/NCBI
11	Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI
12	Jin H, Luo S, Wang Y, Liu C, Piao Z, Xu M, Guan W, Li Q, Zou H, Tan QY, et al: miR-135b stimulates osteosarcoma recurrence and lung metastasis via notch and Wnt/β-catenin signaling. Mol Ther Nucleic Acids. 8:111–122. 2017. View Article : Google Scholar : PubMed/NCBI
13	Thayanithy V, Sarver AL, Kartha RV, Li L, Angstadt AY, Breen M, Steer CJ, Modiano JF and Subramanian S: Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone. 50:171–181. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hill KE, Kelly AD, Kuijjer ML, Barry W, Rattani A, Garbutt CC, Kissick H, Janeway K, Perez-Atayde A, Goldsmith J, et al: An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. J Hematol Oncol. 10:1072017. View Article : Google Scholar : PubMed/NCBI
15	Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, et al: Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells. 29:32–45. 2011. View Article : Google Scholar : PubMed/NCBI
16	Sullivan KE, Rojas K, Cerione RA, Nakano I and Wilson KF: The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells. Oncotarget. 8:22325–22343. 2017. View Article : Google Scholar : PubMed/NCBI
17	Duan JJ, Cai J, Guo YF, Bian XW and Yu SC: ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int J Cancer. 139:965–975. 2016. View Article : Google Scholar : PubMed/NCBI
18	Biermann JS, Chow W, Reed DR, Lucas D, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, et al: NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J Natl Compr Canc Netw. 15:155–167. 2017. View Article : Google Scholar : PubMed/NCBI
19	Steffner RJ and Jang ES: Staging of bone and soft-tissue sarcomas. J Am Acad Orthop Surg. 26:e269–e278. 2018. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Yi H, Geng L, Black A, Talmon G, Berim L and Wang J: The miR-487b-3p/GRM3/TGFβ signaling axis is an important regulator of colon cancer tumorigenesis. Oncogene. 36:3477–3489. 2017. View Article : Google Scholar : PubMed/NCBI
22	John AA, Prakash R and Singh D: miR-487b-3p impairs osteoblastogenesis by targeting Notch-regulated ankyrin-repeat protein (Nrarp). J Endocrinol. 241:249–263. 2019. View Article : Google Scholar : PubMed/NCBI
23	Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T: Opinion: Migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer. 5:744–749. 2005. View Article : Google Scholar : PubMed/NCBI
24	Li F, Tiede B, Massagué J and Kang Y: Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res. 17:3–14. 2007. View Article : Google Scholar : PubMed/NCBI
25	He H, Ni J and Huang J: Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett. 7:1352–1362. 2014. View Article : Google Scholar : PubMed/NCBI
26	Sullivan KE, Cerione RA and Wilson KF: ALDH1A3 in CSCs. Aging (Albany NY). 9:1351–1352. 2017. View Article : Google Scholar : PubMed/NCBI
27	Xu X, Chai S, Wang P, Zhang C, Yang Y, Yang Y and Wang K: Aldehyde dehydrogenases and cancer stem cells. Cancer Lett. 369:50–57. 2015. View Article : Google Scholar : PubMed/NCBI